-
Media Release
RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
-
Media Release
Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case
-
Media Release
Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case
-
Media Release
Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
-
Media Release
Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
-
Media Release
Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
-
Media Release
Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
-
Media Release
Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa® in Women With Early-Stage Breast Cancer
-
Media Release
Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa® in Women With Early-Stage Breast Cancer
-
Media Release
RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
-
Media Release
RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
-
Media Release
Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting